Expanding role of coformulations in the treatment of HIV infection: Impact of fixed-dose combinations

AIDS Reader

Volumn 14, Issue 10, 2004, Pages

  Valenti, William M ^a,b  

^a Podiatry   (United States)

^b UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

Author keywords

Antiretroviral therapy; Fixed dose combinations; HIV AIDS; Nucleoside reverse transcriptase inhibitors

Indexed keywords

ABACAVIR PLUS LAMIVUDINE; ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; ANTIRETROVIRUS AGENT; ATAZANAVIR; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; LAMIVUDINE; LAMIVUDINE PLUS NEVIRAPINE PLUS STAVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR PLUS RITONAVIR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR DISOPROXIL; UNCLASSIFIED DRUG; ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CLINICAL TRIAL; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DRUG APPROVAL; DRUG CAPSULE; DRUG COST; DRUG EFFICACY; DRUG FORMULATION; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; HEALTH CARE ACCESS; HEALTH CARE COST; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LOW DRUG DOSE; PATIENT COMPLIANCE; PILL; QUALITY OF LIFE; REVIEW; SIDE EFFECT; TREATMENT OUTCOME; ADOLESCENT; ADULT; ARTICLE; DRUG COMBINATION; ECONOMICS; HEALTH; METHODOLOGY; UNITED STATES;

ADOLESCENT; ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DRUG APPROVAL; DRUG COMBINATIONS; DRUG COSTS; HIV INFECTIONS; HUMANS; PATIENT COMPLIANCE; UNITED STATES; WORLD HEALTH;

EID: 6944247673     PISSN: 10530894     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (51)

1. Chesney M. Adherence to HAART regimens. AIDS Patient Care STDS. 2003;17:169-177.
2. Celentano DD, Vlahov D, Cohn S, et al. Self-reported antiretroviral therapy in injection drug users. JAMA. 1998;280:544-546.
3. Sherer R. Adherence and antiretroviral therapy in injection drug users. JAMA. 1998;280:567-568.
4. Jordan J, Toison J, Delea T, et al. Impact of fixed-dose combination zidovudine/lamivudine on adherence to antiretroviral therapy: a retrospective claims-based cohort study. Presented at the 6th International Congress on Drug Therapy in HIV Infection; November 17-21, 2002; Glasgow, UK. Abstract P97.
5. Bartlett JA, DeMasi R, Quinn J, et al. Overview of the effectiveness of triple combination therapy in antiretroviral-naive HIV-1 infected adults. AIDS. 2001;15:1369-1377.
6. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. March 23, 2004. Available at: http://www.aidsinfo.nih.gov/ guidelines/adult/default_db2.asp?id=50. Accessed September 1, 2004.
7. Mocroft A, Vella S, Benfield TL, et al. Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group. Lancet. 1998;352:1725-1730.
8. Palella FJ Jr, Delaney KM, Moorman AC et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med. 1998;338:1725-1730.
9. Egger M, Hirschel B, Francioli P, et al. Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: prospective multicentre study. Swiss HIV cohort study. BMJ. 1997;315:1194-1199.
10. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N Engl J Med. 1997;337:725-753.
11. Montaner JS, Reiss P, Cooper D, et al. A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS Trial. Italy, the Netherlands, Canada and Australia Study. JAMA. 1998;279:930-937.
12. Clumeck N. Choosing the best initial therapy for HIV-1 infection. N Engl J Med. 1999;341:1925-1926.
13. Kitahata MM, Koepsell TD, Deyo RA, et al. Physicians' experience with the acquired immunodeficiency syndrome as a factor in patients' survival. N Engl J Med. 1996;334:701-706.
14. Kitahata MM, Van Rompaey SE, Shields A. Physician experience in the care of persons with HIV infection is associated with earlier adoption of new antiretroviral therapy. J Acquit Immune Defic Syndr. 2000;24:106-114.
15. Sacks L. Fixed dose combinations: When are clinical trials needed? Available at: http://www.who.int/medicines/organization/par/FDC/WHOSacksFDCs. ppt. Accessed September 1, 2004.
16. Kastury N, Singh S, Ansari KU. An audit of prescription for rational use of fixed dose drug combinations. Indian J Pharmacol. 1999;31:367-369.
17. Nies AS, Spielberg SP. Principles of therapeutics. In: Hardman JG, Limbird LE, Molinoff PB, et al, eds. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 9th ed. New York: McGraw-Hill; 1996:43-62.
18. Guidance for Industry. Fixed dose combination and co-packaged drug products for treatment of HIV. Draft Guidance. US Department of Health and Human Services, Food and Drug Administration. Center for Drug Evaluation and Research. May 2004. Available at: http://www.fda.gov/oc/initiatives/hiv/ hivguidance.html. Accessed September 1, 2004.
19. FDA approves Kaletra for HIV infection. FDA Talk Paper. September 15, 2000. Available at: http://www.fda.gov/bbs/topics/ANSWERS/ANS01036.html. Accessed September 1, 2004.
20. Corbett AH, Lim ML, Kashuba AD. Kaletra (lopinavir/ritonavir). Ann Pharmacother. 2002;36:1193-1203.
21. Experts identify compliance as biggest obstacle to HIV management. Vanguard. December 23, 2003. Available at: http://www.vanguardngr.com/articles/ 2002/features/fe123122003.html. Accessed September 1, 2004.
22. Fleck F. WHO approves combination pills for HIV/AIDS. BMJ. 2003;327:1067.
23. Floyd K, Kumaranayake L, Getahun H, et al. Resources required for collaborative TB and HIV/AIDS program activities in the context of the World Health Organization's "3 by 5" initiative. Presented at the XV International AIDS Conference; July 11-16, 2004; Bangkok, Thailand. Abstract TuOrD1209.
24. Laurent C, Kouanfack C, Koulla-Shiro S, et al. Effectiveness and safety of a generic fixed-dose combination of nevirapine, stavudine, and lamivudine in HIV-1-infected adults in Cameroon: open-label multicentre trial. Lancet. 2004;364:29-34.
25. Oyugi JH, Byakika JT, Ragland K, et al. Treatment outcomes and adherence to generic Triomune and Maxivir therapy in Kampala, Uganda. Presented at the XV International AIDS Conference; July 11-16, 2004; Bangkok, Thailand. Abstract WeOrB1323.
26. Akhlaghi L, Lee D. Review of antiretroviral therapy (ART) guidelines in selected countries of Africa and the Caribbean: a challenge for optimizing treatment and product supply. Presented at the XV International AIDS Conference; July 11-16, 2004; Bangkok, Thailand. Abstract ThPeE7956.
27. Russell AI, Lugg A, Baker B, et al. Contrasting United States government (USG) trade policy regarding intellectual property rights (IPRs) with the World Trade Organization's (WTO) Doha Declaration on TRIPS and Public Health. Presented at the XV International AIDS Conference; July 11-16, 2004; Bangkok, Thailand. Abstract ThPeC7570.
28. Wang M. Improving WTO rules on HIV pharmaceutical patent for developing countries. Presented at the 15th International AIDS Conference; July 11-16, 2004; Bangkok, Thailand. Abstract MoOrE1071.
29. US Food and Drug Administration. Expedited review process for HIV/AIDS drugs announced. May 16, 2004. Available at: http://www.fda.gov/oc/initiatives/ hiv/default.htm. Accessed September 1, 2004.
30. World Bank. WHO to disclose AIDS proposal to bring low-cost drugs to poor. October 10, 2003. Available at: http://web.worldbank.org/WBSITE/EXTERNAL/ NEWS/0,,date:10-27-2003~ menuPK:278083~pagePK:34392~piPK:34427~ theSitePK:4607,00.html#Story3. Accessed September 1, 2004.
31. WHO adds new fixed dose combinations to its list of quality products for AIDS treatment. December 1, 2003. Available at: http://www.who.int/mediacentre/ news/releases/2003/pr90/en/print.html. Accessed September 1, 2004.
32. Meldrum J. Nevirapine-based fixed-dose ARVs. AIDSMA Web site. Available at: http://www.aidsmap.com/web/pb3/eng/391d2c51-0d82-405a-9720-010ded63a8a6.htm. Accessed September 1, 2004.
33. Palmer NB, Salcedo J, Miller AL, et al. Psychiatric and social barriers to HIV medication adherence in triply diagnosed methadone population. AIDS Patient Care STDS. 2003;17:635-644.
34. Lucas GM, Flexner CW, Moore RD. Directly administered antiretroviral therapy in the treatment of HIV infection: benefit or burden? AIDS Patient Care STDS. 2002;16:527-535.
35. Park-Wyllie LY, Phillips EJ. Challenges of adherence management in human immunodeficiency virus pharmacotherapy. Can J Clin Pharmacol. 2003;10:189-195.
36. Laurence J. Simplifying HIV therapeutics, and the global treatment of AIDS. AIDS Reader. 2003;13:5-6.
37. Sethi AK, Celentano DD, Gange SJ, et al. Association between adherence to antiretroviral therapy and human immunodeficiency virus drug resistance. Clin Infect Dis. 2003;37:1112-1118.
38. Brigado LF, Rodrigues R, Casseb J, et al. Impact of adherence to antiretroviral therapy in HIV-1-infected patients at a university public service in Brazil. AIDS Patient Care STDS. 2001;15:587-593.
39. Stone VE, Jordan J, Tolson J, Pilon T. Potential impact of once daily regimens on adherence to HAART. Presented at the 40th Annual Meeting of the Infectious Diseases Society of America; October 24-27, 2002; Chicago. Abstract 486.
40. Jordan J, Carranza-Rosenzweig J, Pathak D, Pilon T. Perceived influence of regimen characteristics on adherence. Presented at the 5th International Congress on Drug Therapy in HIV Infection; October 22-26, 2000; Glasgow, UK. Abstract 121.
41. Ryan GW, Wagner GJ. Pill taking "routinization": a critical factor to understanding episodic medication adherence. AIDS Care. 2003;15:795-806.
42. Atazanavir (Reyataz) and emtricitabine (Emtriva) for HIV infection. Med Lett Drugs Ther. 2003;45:90-92.
43. Raffi F. Maximizing the effectiveness of highly active antiretroviral therapy: is there a role for quadruple regimens? Adv Stud Nurs. 2002;2:827-831.
44. Freedberg KA, Losina E, Weinstein MC, et al. The cost effectiveness of combination antiretroviral therapy for HIV infection. N Engl J Med. 2001;344:824-831.
45. Bozzette SA, Joyce G, McCaffrey DF, et al. Expenditures for the care of HIV-infected patients in the era of highly active antiretroviral therapy. N Engl J Med. 2001;344:817-823.
46. Valenti WM. HAART is cost-effective and improves outcomes. AIDS Reader. 2001;11:260-262.
47. Tramarin A, Campostrini S, Postma MJ, et al. A multicentre study of patient survival, disability, quality of life and cost of care: among patients with AIDS in northern Italy. Pharmacoeconomics. 2004;22:43-53.
48. Stoll M, Claes C, Schulte E, et al. Direct costs for the treatment of HIV-infection in a German cohort after the introduction of HAART. Eur J Med Res. 2002;7:463-471.
49. Krentz HB, Auld MC, Gill MJ, HIV Economic Study Group. The changing direct costs of medical care for patients with HIV/AIDS, 1995-2001. CMAJ. 2003;169:106-110.
50. Combivir. Test Positive Aware Network. Available at: http://www.tpan.com/ publications/drug_guide/drug_combivir.html. Accessed September 1, 2004.
51. Goldie SJ, Paltiel AD, Weinstein MC, et al. Projecting the cost-effectiveness of adherence interventions in persons with human immunodeficiency virus infection. Am J Med. 2003;115:632-641.